California AB1843 prohibits health care service plans from requiring prior authorization for direct-acting antiviral drugs for hepatitis C treatment.

California AB1843 mandates that health care service plans cannot require prior authorization for direct-acting antiviral drugs that are medically necessary for treating hepatitis C. This requirement does not apply if the United States Food and Drug Administration has approved therapeutic equivalents of a pangenotypic drug, device, or product for hepatitis C treatment. The bill also specifies that it does not apply to Medi-Cal managed care contracts with the State Department of Health Care Services.

California AB1843 prohibits health care service plans from requiring prior authorization for direct-acting antiviral drugs for hepatitis C treatment.

California AB1843 mandates that health care service plans cannot require prior authorization for direct-acting antiviral drugs that are medically necessary for treating hepatitis C. This requirement does not apply if the United States Food and Drug Administration has approved therapeutic equivalents of a pangenotypic drug, device, or product for hepatitis C treatment. The bill also specifies that it does not apply to Medi-Cal managed care contracts with the State Department of Health Care Services.